
Sotorasib is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
from FDA,2023.04
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Sotorasib (Lumakras) for the treatment of adult patients with KRAS G12C-mutated local···【more】
Article source:Lucius LaosRelease date:2026-03-23Recommended:40
On January 17, 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the combination of Sotorasib (Lumakras) and Panitumumab (Vectibix) for the treatm···【more】
Article source:Lucius LaosRelease date:2026-03-23Recommended:43
Sotorasib, also known as AMG-510, is an orally bioavailable drug that falls under the category of selective KRAS G12C covalent inhibitors. By locking the KRAS G12C protein in an in···【more】
Article source:Lucius LaosRelease date:2024-08-05Recommended:264
Sotorasib, a novel small molecule targeted therapeutic agent, presents a promising treatment avenue for patients harboring the KRAS G12C mutation. The KRAS gene plays a pivotal rol···【more】
Article source:Lucius LaosRelease date:2024-08-05Recommended:347
Sotorasib, also known as AMG-510, is an orally bioavailable drug that falls under the category of selective KRAS G12C covalent inhibitors. By locking the KRAS G12C protein in an in···【more】
Article source:Lucius LaosRelease date:2024-07-09Recommended:357

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: